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Abstract
Leukocyte chemotactic factor-2 (LECT2) amyloidosis has been described as being associated with
kidney disease; however, no clinical manifestations outside of the kidney have been previously re-
ported. We describe a patient presenting with pulmonary-renal syndrome found to have deposition
of amyloidogenic LECT2 (ALECT2) within both the lung and the kidney. This case is unique in regard
to both the patient’s clinical presentation of pulmonary-renal syndrome in the setting of amyloido-
sis and the biopsy finding of ALECT2 deposition within the lung. It also emphasizes the importance
of tissue diagnosis in such cases, given that amyloidosis was not initially considered in the differen-
tial diagnosis.
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Background
Amyloidosis represents an uncommon group of disorders
which results from abnormal deposition of protein fibrils ar-
ranged in cross-β sheet quaternary structures [1]. An ex-
panding list of native proteins has been implicated, with
amyloidogenic leukocyte chemotactic factor 2 (ALECT2)
being a recent addition [2]. Deposition of ALECT2 within the
kidney is a known cause of kidney dysfunction; however,
extra-renal manifestations and pulmonary ALECT2 depo-
sition have not been reported. Herein, we report a patient
presenting with pulmonary-renal syndrome found to have
ALECT2 deposition within both the lung and the kidney.
Clinical report
An 84-year-old Mexican-American man with diabetes melli-
tus, hypertension, hyperlipidemia and prostatic adenocarci-
noma, status-post prostatectomy presented with shortness
of breath and fatigue, which had progressed over 2 weeks.
Three days prior to presentation, he experienced an acute
worsening of his respiratory status, prompting him to seek
emergency care. The patient did not report any neurologic
symptoms, rash, recent fever or infection. At presentation,
he was hypoxic with oxygen saturations of 80% on room air.
An arterial blood gas showed a pH 7.43 (reference range
7.35–7.45), partial carbon dioxide of 28 mm Hg (reference
range 35–45 mm Hg) and partial oxygen of 61 mm Hg (re-
ference range 80–100 mm Hg) on inspired oxygen of 60%.
Physical examination revealed moderate respiratory distress
and edema of the lower extremities. A computerized tom-
ography scan of the chest showed bilateral opacities in a
pattern that was felt to possibly represent diffuse alveolar
hemorrhage (Figure 1).
Initial chemistries were significant for a carbon dioxide of
17 mmol/L (17 meq/L), blood urea nitrogen of 26.4 mmol/L
(74 mg/dL) and a serum creatinine of 406.6 μmol/L (4.6 mg/
dL) with an estimated glomerular filtration rate (eGFR) of
12 mL/min/1.73 m2 calculated by the four-variable MDRD
(Modification of Diet in Renal Disease) study equation. A
complete blood count showed a white blood cell count of
10.4 × 109/L (10.4 × 103/μL), hemoglobin of 52 g/L (5.2 g/dL)
and a normal platelet count of 335 × 109 /L (335 × 103 /μL).
Urinalysis revealed a specific gravity of 1.011, pH 5.0, 3+
protein, 1+ blood and negative leukocyte esterase and
nitrites. Spot urine protein-to-creatinine ratio showed sub-
nephrotic proteinuria with a ratio of 1.5. Serologic studies
revealed the presence of perinuclear antineutrophil cyto-
plasmic antibody (P-ANCA) of 1:160 (reference range <1:20).
Immunoglobulin G (IgG) myeloperoxidase antibody (MPO)
was 385 AU/mL (normal: <19 AU/mL). Serum and urine
protein electrophoresis demonstrated a monoclonal IgM
kappa band. Given the patient’s markedly elevated anti-
MPO titer, a thorough review of his medications was per-
formed. No medications associated with ANCA production
were identified.
Hemodialysis was initiated due to acute kidney failure
and volume overload, and the patient was transferred to
the intensive care unit where he required non-invasive
positive pressure ventilation and developed a transient
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episode of hemoptysis. Shortly after the initiation of hemo-
dialysis, the patient was weaned from positive airway
pressure ventilation. Pulse intravenous methylprednisolone
was initiated and plasmapheresis was started as empiric
therapy for a presumed diagnosis of microscopic polyangii-
tis with diffuse alveolar hemorrhage. Kidney and lung biop-
sies were performed for tissue diagnosis. A bone marrow
biopsy was also obtained which showed no plasma cell
dyscrasia.
The kidney biopsy showed renal cortex containing up to
eight glomeruli per level, of which two were globally scler-
osed. The non-sclerotic glomeruli showed segmental me-
sangial expansion by extracellular amorphous material
which did not stain with Jones methenamine silver stain,
stained weakly on periodic acid Schiff stain, and demon-
strated a gray hue on the trichrome stain. Glomerular ca-
pillaries were patent without hypercellularity and no
fibrinoid necrosis or crescents were identified. The intersti-
tium and walls of arteries and arterioles demonstrated
diffuse infiltration by the same amorphous material. There
were no lesions of vasculitis. A Congo red stain was per-
formed and showed strong staining of the mesangial, in-
terstitial and vascular deposits (Figure 2A). Apple-green
birefringence was demonstrated upon polarization of the
Congo red stain, confirming the presence of amyloid
(Figure 2B).
Immunofluorescence microscopy was performed using
antisera to human immunoglobulin G (IgG), IgA, IgM, C1q,
C3, albumin, fibrinogen and kappa/lambda light chains
(DAKO Corporation - Carpinteria, CA) and graded on a scale
of 0–4+. Weak and smudgy staining (1–2+) was seen in the
interstitium and vessel walls for IgG, IgA, IgM and both
kappa and lambda light chains. There was no significant
staining for C3, C1q, fibrinogen or albumin or evidence of
immunoglobulin restriction. Ultrastructural examination re-
vealed extensive haphazard deposition of fibrils ranging in
thickness from 6–10 nm within the interstitium and focally
within mesangial areas (Figure 2C). The size and distribution
of the fibrils were consistent with amyloid. An immunohis-
tochemical workup was initiated to better classify the
amyloid subtype, which included stains for kappa and
lambda light chains, amyloid A and prealbumin (transthyre-
tin), all of which were negative (DAKO Corporation). Further
immunohistochemical evaluation with anti-LECT2 anti-
bodies (performed at Nephropath Laboratories—Little
Rock, AR) demonstrated diffuse positive staining within the
amyloid deposits (Figure 2D).
Due to uncertainty in the lung pathology, wedge biopsies
of the upper, middle and lower lobes of the right lung were
performed. Biopsies showed multifocal, small deposits of
the same extracellular amorphous material within the al-
veolar septa and walls of small and large vessels. These de-
posits were strongly positive on the Congo red stain
(Figure 2E) and demonstrated apple-green birefringence
upon polarization, consistent with amyloid. There were no
lesions of vasculitis. Immunohistochemical staining with
anti-LECT2 antibodies was positive within the amyloid de-
posits (Sigma Life Sciences—St. Louis, MO) (Figure 2F).
In summary, kidney and lung biopsies both demon-
strated deposition of amyloid showing positive immuno-
histochemical staining for LECT2. No lesions of vasculitis
were identified in any of the biopsy specimens and cres-
cents were not seen in the kidney biopsy.
The patient was discharged 36 days after his initial pres-
entation with a creatinine of 203.3 μmol/L (2.3 mg/dL,
eGFR: 27 mL/min/1.73 m2). Steroids were gradually
tapered off at 6 months, and the patient is currently main-
tained on azathioprine. Eight months after his initial pres-
entation, his creatinine clearance improved to 20–25 mL/
min and he no longer required hemodialysis.
Discussion
Leukocyte chemotactic factor 2 (LECT2) is a recently de-
scribed amyloidogenic protein and potential cause of
kidney disease. Originally characterized in 1998, human
LECT2 is predominantly synthesized by hepatocytes. Along
with neutrophil chemotactic properties, it is also believed
that LECT2 plays a role in tissue growth and repair following
damage. The latter function has been proposed given the
similarities between human LECT2 and its bovine counter-
part: chondromodulin-II [3–5]. LECT2 amyloidosis is now a
well-described cause of kidney injury; however, extra-renal
manifestations have not been reported [2]. Since 1971,
when monoclonal light chain became the first chemically
characterized amyloid protein, a growing list of amyloido-
genic proteins has been amassed, including, but not
limited to, monoclonal light chain (AL), amyloid A protein
(AA), transthyretin (ATTR), apolipoproteins AI (AApoAI) and
AII (AApoAII), lysozyme (ALys), gelsolin (AGel) and β-2 mi-
croglobulin [6, 7]. The mechanism of amyloidogenesis is
quite variable, including hereditary mutation, protein over-
production and decreased protein excretion. In the case of
ALECT2, the exact mechanism of disease has not been fully
elucidated; however, a genetic component is suspected [1].
The LECT2 gene has beenmapped to chromosome 5q31.1–
32 and contains four exons and three introns. The four
exons code for a 151 amino acid protein, which is 133
amino acids in its secreted form [3]. In one published
series, four of four patients with LECT2 amyloidosis who un-
derwent LECT2 gene analysis were identified as homozy-
gous for the G allele, substituting valine at position 40 of
the mature protein for isoleucine, which is found in the A
allele [4]. This single amino acid switch may result in a pro-
pensity to form amyloid fibrils [4]. The vast majority of re-
ported cases have occurred in patients of Mexican descent,
also supporting a genetic role [8].
Published reports and case series of clinical disease due
to LECT2 amyloidosis have thus far been limited to depo-
sition within the kidney. One report has demonstrated
Fig. 1. CT scan of chest demonstrates patchy and confluent, groundglass
and consolidated opacities in both lungs, in a pattern consistent with
diffuse alveolar hemorrhage.
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incidentally discovered ALECT2 within hepatic, splenic,
colonic and adrenal tissue [9]. Murphy et al. described a
series of 10 patients with kidney-limited LECT2 amyloido-
sis, representing 2.5% of amyloid cases diagnosed by
kidney biopsy over an 8.5-year period. Clinically, patients
presented with varying degrees of kidney insufficiency,
and the majority presented with only minimal proteinuria
in contrast to AL and AA, which often present with ne-
phrotic-range proteinuria. Histologically, ALECT2 depo-
sition was predominantly localized within the interstitium
and mesangial regions, although all compartments of the
kidney parenchyma may be involved [4,10]. Other pub-
lished case reports have shown similar clinical and histo-
logic features of ALECT2 amyloidosis [10,11].
Like the kidney, the lung may be involved in systemic
amyloidosis with the most frequent subtypes being AL
and AA amyloid. ALECT2 has not been previously reported
in the lung. Deposition of amyloid within the pulmonary
parenchyma is the most common manifestation of amy-
loidosis within the respiratory system and may occur in a
nodular or diffuse pattern [12]. In nodular pulmonary
amyloidosis, deposition is typically localized and is often
an incidental radiographic finding in the lung periphery
[13]. Diffuse pulmonary involvement is most often seen in
the setting of systemic AL amyloidosis, and although
severe clinical manifestations are not common, hemopty-
sis and fatal pulmonary hemorrhage have been reported
[14].
The case we present here is unique both in its clinical
presentation and in the biopsy findings. The positive ANCA
serology and the clinical picture of pulmonary-renal syn-
drome were highly suspicious for a systemic small vessel
vasculitis. Reports of systemic amyloidosis presenting with
pulmonary-renal syndrome are scant in the literature. A
case of systemic AA amyloidosis in a patient with dys-
trophic epidermolysis bullosa resulting in recurrent
Fig. 2. (A) A Congo red stain performed on kidney biopsy shows deposition of Congophilic material within the glomeruli (solid arrow), arterial wall (arrow
head) and interstitium (dashed arrow) (Congo red stain, original magnification: ×200). (B) Polarization of the Congo red stain demonstrates apple-green
birefringence, consistent with amyloid (original magnification: ×200). (C) Electron microscopy on the kidney biopsy shows haphazard deposition of fibrils
measuring 6–10 nm in thickness, consistent with amyloid (original magnification: ×20 000). (D) Staining for LECT2 by immunohistochemistry shows strong
and diffuse staining within glomerular, interstitial and vascular deposits within the kidney biopsy (original magnification: ×200). (E) Wedge biopsies of the
lung show multifocal deposition of Congophilic material within alveolar septa (Congo red stain, original magnification: ×400). (F) Amyloid deposits within
a small vessel of the lung show positive staining for LECT2 by immunohistochemistry (original magnification: ×400).
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pulmonary infections and nephrotic syndrome has been
reported; however, hemoptysis was not present and crea-
tinine clearance was normal [15]. Histopathologically, this
case is unique both in the extent and distribution of the
amyloid deposition and the amyloid protein itself. To our
knowledge, this is the first description of LECT2 amyloido-
sis causing clinical disease outside of the kidney and the
first description of LECT2 deposition in the lung.
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